Revolution Medicines announced the pricing of concurrent public offerings totaling $2.0 billion, consisting of 10.56 million shares of common stock at $142.00 per share ($1.5 billion) and $500 million in 0.50% convertible senior notes due 2033. The offerings were upsized from previously announced amounts. Net proceeds will be used for R&D, commercialization, and general corporate purposes.

Revolution Medicines shares surged 39.97% in premarket trading following positive Phase 3 RASolute 302 trial results showing its drug daraxonrasib doubled overall survival (13.2 months vs. 6.7 months) compared to standard chemotherapy for metastatic pancreatic cancer. The company plans regulatory submissions and will present findings at the 2026 ASCO Annual Meeting. However, Merck ended acquisition discussions with Revolution Medicines over valuation disagreements.

Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion ($53 per share) to bolster its pipeline ahead of Keytruda's patent expiry in 2028. The deal focuses on Terns' early-stage CML treatment TERN-701. However, analysts suggest the offer may undervalue the asset and could attract competing bids from other pharmaceutical companies.

Nextech Invest, a Switzerland-based biotech-focused fund, increased its stake in Relay Therapeutics by 855,097 shares (~$6.1 million). The purchase brings Relay to 3.85% of Nextech's portfolio. Relay's stock has surged 197% over the past year, driven by its computational drug discovery platform and clinical-stage pipeline including lead candidates RLY-4008 and RLY-2608.

Hedge fund BVF fully exited its position in Protagonist Therapeutics (PTGX), selling 2.56 million shares worth $170.12 million. Despite the stock rallying 120% over the past year, the fund's exit reflects a disciplined capital rotation strategy following the company's New Drug Application submission for rusfertide in polycythemia vera, marking a shift from clinical-stage risk to regulatory execution risk.

Hedge fund BVF invested $52 million in Disc Medicine (IRON) by acquiring 650,000 shares in Q4, demonstrating conviction in the clinical-stage biotech company despite recent FDA setbacks. The investment was made before the FDA's Complete Response Letter in February and a subsequent 20% stock decline. With $791 million in cash runway through 2029, Disc Medicine's investment thesis now hinges on Phase 3 APOLLO trial data expected in Q4 and a potential FDA decision by mid-2027.

Breakthru Medicine, a cancer-focused biotech startup founded by industry veterans Steve Potts, Mark Mulvihill, and Brian Barnett, has closed a $60M Series A financing round. The company is developing disruptive therapeutic modalities including small molecules, next-generation ADC payloads, and molecular glues to address unmet cancer treatment needs. The founding team has collectively been involved in over a dozen approved or late-stage therapies, many with FDA Breakthrough Therapy Designation.

Revolution Medicines stock dropped nearly 17% after The Wall Street Journal reported that Merck withdrew from acquisition discussions with the biotech company. The two companies failed to agree on the buyout price, though talks could potentially resume. Other pharmaceutical companies including AbbVie have also been reported as interested acquirers.

Natural gas surged over 30% to above $6/MMBtu due to Winter Storm Fern, marking the largest weekly gain ever for a Nymex contract. Silver jumped 13% to $116/oz, its best day since 2008, while gold rose 2.2% to $5,100. U.S. equities gained modestly with the S&P 500 and Nasdaq up 0.7%, driven by technology and mining stocks. Dollar weakness supported the commodity rally.

Erasca (ERAS) stock declined 7.33% on Monday following news that Merck ended acquisition discussions with competitor Revolution Medicines over valuation disagreements. The deal would have valued Revolution Medicines at approximately $30 billion. Both companies develop RAS-pathway cancer therapies, and the failed deal sparked investor concerns about the sector's valuation environment.

Merck & Co. has ended acquisition discussions with Revolution Medicines after the two companies disagreed on valuation. The deal was reportedly valued between $28-32 billion, with talks centered around $30 billion. Revolution Medicines shares plummeted 22.74% in premarket trading following the news. Despite the setback, talks could potentially restart or another bidder may emerge, with clinical trial data expected in the first half of 2026.

Ten large-cap stocks surged last week driven by defense spending increases, AI infrastructure deals, and acquisition speculation. Top performers included Regencell Bioscience (89.45% gain), Revolution Medicines (51.38% on Merck acquisition talks), Kratos Defense (36.12% on military budget expansion), AeroVironment (35.86% on Army partnership), Karman Holdings (33.91% on acquisition deal), SanDisk (33.15% on pricing strategy), Bloom Energy (30.55% on credit facility), Oklo (29.04% on Meta power deal), Applied Digital (29.48% on earnings beat), and Figure Technology (29.33% on analyst upgrade).